FDA pushed the DSCSA small dispenser exemption out to November 27, 2027. It covers the electronic, package-level requirements. It doesn't cover buying from authorized partners, keeping records, or handling suspect product. Here's the plain-English version.
· 6 min read
Written and clinically reviewed by Jacob Fuchs, PharmD
Reviewed on
FDA extended the DSCSA small dispenser exemption by one year. If the company that owns your pharmacy or clinic has 25 or fewer full-time pharmacists and pharmacy technicians, you're exempt from the electronic, package-level parts of the law until November 27, 2027. You're not exempt from the rest of it.
That second sentence is the one people skip. So let's go through both halves.
I'm a pharmacist, not your lawyer. This is the plain-English version of what FDA published. If you have a weird ownership structure, run it past counsel.
On August 6, 2026, FDA issued a letter exempting small dispensers from certain requirements of section 582 of the Food, Drug, and Cosmetic Act until November 27, 2027 (FDA exemption letter). The previous exemption was set to run out on November 27, 2026.
The details that matter:
FDA's definition: a dispenser is small if "the corporate entity that owns the dispenser has a total of 25 or fewer full-time employees licensed as pharmacists or qualified as pharmacy technicians" (FDA exemption letter).
Two things trip people up.
It's counted at the company level. Three stores with 10 pharmacists and techs each is 30, not 10. If you're part of a group, count the group.
Clinics are dispensers too. The law defines a dispenser as a retail pharmacy, a hospital pharmacy, a chain, or "any other person authorized by law to dispense or administer prescription drugs" (21 U.S.C. 360eee). Physician practices, surgery centers, and clinics that buy and administer drugs fall under that definition.
The letter doesn't say how its count works for a practice with no pharmacists or techs on staff. Read literally, zero is 25 or fewer. Get that confirmed by counsel, not by a blog post. That includes this one.
Yes, and it's older than any of these exemptions. The statute says the product tracing requirements in section 582(d)(1) and the verification requirements in section 582(d)(4) don't apply to "licensed health care practitioners authorized to prescribe or administer medication under State law," or to licensed staff working under their supervision, who dispense or administer drugs in the usual course of professional practice (21 U.S.C. 360eee-1(d)(5)).
Notice what that exception doesn't mention. It doesn't cover the requirement to buy only from authorized trading partners, which sits in a different paragraph, (d)(3). The enhanced electronic tracing section, 582(g), has no similar practitioner exception in its text. How FDA applies 582(g) to a given practice is a question for your counsel.
Through November 27, 2027, small dispensers and, where applicable, their trading partners can keep doing things the current way instead of the fully electronic, package-level way (FDA exemption letter):
| Requirement (section 582) | What the exemption lets you keep doing |
|---|---|
| (g)(1)(A): secure, interoperable electronic data exchange | Provide, capture, and keep transaction information and statements using your current methods |
| (g)(1)(B): a product identifier for every package in the data | Exchange transaction information without package-level identifiers |
| (g)(1)(C): package-level verification systems | Use your current verification methods |
| (g)(1)(D): electronic response to recall and suspect-product requests | Respond using your current methods |
| (g)(1)(E): gathering tracing data back to the manufacturer | Use your current methods (dispensers only) |
| (g)(1)(F): saleable returns | Your trading partners can keep accepting your saleable returns the current way |
| (d)(4)(A)(ii)(II) and (B)(iii): verifying the product identifier on the statutory share of suspect or illegitimate product | Skip that specific product-identifier check |
The letter is explicit that the exemptions "do not apply to other requirements in section 582."
Everything in section 582(d) that the exemption doesn't name. In plain English (21 U.S.C. 360eee-1(d)):
The licensed practitioner exception above changes some of this for practitioners. The authorized trading partner rule isn't part of it.
Everyone bigger than you. FDA's earlier exemptions ended on these dates (FDA):
So your manufacturers and your wholesaler are already expected to be on the electronic system. The small dispenser exemption lets them keep dealing with you the current way for one more year. After November 27, 2027, unless FDA acts again, that grace period is over.
1. Write down your headcount as of November 27, 2026, and how you counted it. If anyone ever asks, "we figured we were small" isn't a record. 2. Tell your suppliers you're relying on the exemption. FDA recommends it, and it heads off held orders. 3. Check your paperwork today. Can you pull up the transaction information and statement for something you bought eight months ago? If not, fix that before you worry about 2027. 4. Write a one-page suspect-product procedure. Cover who quarantines the product, where it goes, who investigates, and who makes the 24-hour notification. 5. Pick your electronic system now, not in October 2027. Everyone who waits until the last quarter ends up in the same vendor queue at the same time.
Premier offers free DSCSA compliance software, with no purchase required. Every Premier order also comes with the DSCSA transaction information and statement. Start with our DSCSA compliance resources, or open a free account. Credential review typically takes 1–2 business days.
Premier Pharma Insights
dscsa-compliance
VAWD is now NABP's Drug Distributor Accreditation. It's voluntary, and it isn't the only check that matters. Under DSCSA you can buy only from authorized trading partners. Here are the four checks that prove a wholesaler qualifies.
dscsa-compliance
FDA has extended certain DSCSA exemptions for qualifying small dispensers until November 27, 2027. The extra time is an implementation window—not a reason to pause. Use this practical plan to strengthen trading-partner controls, electronic tracing, exception handling, and staff readiness.